Investigational Medicinal Product Dossier (IMPD)

Banner with Title


In order to administer the Investigational Medicinal Product (IMP) on human population in the EU countries, the Sponsors must submit clinical trial authorization application and Investigational Medicinal Product Dossier (IMPD) as per the legislation and the detailed scientific information on the IMP. Some of the challenging issues in conducting clinical trials in the EU are:

  • Strategy and planning of Investigational Medicinal Product Dossier (IMPD) submissions in applicable Member States, where clinical trials are planned
  • Integration of clinical material manufacturing, GMP compliance, QP release, import logistics with IMPD submission and conduct of clinical trials
  • Planning of IMPD submissions considering the implementation of new EU Regulation No. 536/2014
  • Trial execution in multiple sites/multiple Member States and subsequent reporting/updates to Investigational Medicinal Product Dossier

Preparation of compliant IMPD submissions as per the EU requirements and managing the challenges for different types of products requires special set of Regulatory expertise. Therefore, to obtain optimal planning and smooth execution of Regulatory submission for complex clinical programs, sponsors must consult a Regulatory expert with prior experience in the EU Regulatory submissions and handling IMPDs.

Freyr assists sponsors in handling and submission of Clinical Trial Authorization (CTA) applications for different types of medicinal products, such as new drugs, Recombinant Protein Products, Vaccines, Stem Cell-Based Products, etc.

Freyr Expertise and Advantages

Freyr Expertise

  • Regulatory strategic support in identifying the optimal IMPD submission approach for conducting clinical trials in multiple Member States (EU) as per the proposed clinical program
  • Expert advice on mitigation plan for product developmental issues/submission risks
  • Gap analysis of developmental data for IMPD application submission, Identify Regulatory deficiencies and recommend submission strategy to mitigate risks
  • Extensive understanding on MAA registration requirements and data correlations from IMPD application to future MA applications
  • Compilation, technical review and submission of CTA applications/IMPD dossier and IMPD updates/amendments for different types of medicinal products
  • Advice for appointment/consultation of QP to address GMP related issues and for release of Investigational medicinal product lots intended for clinical trials
  • Follow-up with Regulatory Agencies as needed for the clinical trial program
  • Regulatory response strategy, preparation and on-time submission of response to the Health Authority (HA) queries pertaining to an Investigational Medicinal Product Dossier